KFSHRC Conducts Nearly Half Of Saudi Arabia's Clinical Trials In Early 2025

King Faisal Specialist Hospital and Research Centre (KFSHRC) led Saudi Arabia's healthcare sector in clinical trials during the first half of 2025. The hospital was responsible for 48% of all clinical trials registered nationwide. It recorded 104 active trials and initiated 80 new studies, enhancing patient access to innovative therapies and expanding future treatment options.

The Saudi National Institute of Health reported that the clinical trials registered in the Kingdom during this period focused on various health conditions. These included cancer, cardiovascular diseases, musculoskeletal disorders, dermatological and autoimmune conditions, gastrointestinal and liver diseases, as well as endocrine and metabolic disorders.

KFSHRC recently announced a significant milestone in gene and cell therapies. They successfully treated the first patient using locally manufactured genetically engineered CAR-T cells. This was part of a Phase I clinical trial for patients with relapsed acute lymphoblastic leukemia, marking a major advancement in medical treatments.

The hospital continues to enhance its research capabilities in advanced therapies. This includes gene and cellular treatments while expanding into new clinical trials that support medical innovation. These efforts align with the objectives of Saudi Vision 2030, reinforcing KFSHRC's role as a leading healthcare institution.

KFSHRC's achievements have not gone unnoticed. In 2025, it was ranked first in the Middle East and North Africa region and 15th globally among the world's top 250 academic healthcare institutions. Additionally, Brand Finance recognized it as the most valuable healthcare brand in Saudi Arabia and the Middle East in 2024.

Furthermore, Newsweek listed KFSHRC among the World's Best Smart Hospitals for 2025. This recognition highlights its commitment to integrating technology with healthcare services to improve patient outcomes and operational efficiency.

KFSHRC's ongoing efforts to advance medical research and innovation are pivotal for the future of healthcare in Saudi Arabia. By leading clinical trials and pioneering new treatments, it plays a crucial role in shaping the country's medical landscape.

With inputs from SPA